Fresenius Kabi Oncology to delist its equity shares
From BSE & NSE
Fresenius Kabi Oncology has received a letter dated 16 April 2013 from its promoter shareholder, Fresenius Kabi (Singapore) notifying the company of its intention to make a voluntary delisting offer to the public shareholders of the company to acquire the entire public shareholding of the company (i.e. 30,063,255 equity shares of Re 1 each, representing 19% of the share capital of the company) and delist the equity shares of the company from the stock exchanges on which the equity shares of the company are presently listed, i.e., Bombay Stock Exchange and National Stock Exchange in accordance with the SEBI (Delisting of Equity Shares) Regulations, 2009.Powered by Capital Market - Live News